NanoViricides (NYSE-A:NNVC) will present its groundbreaking nanomedicine platform at the Global AMR Summit 2024.
The company’s president Dr Anil Diwan will discuss its "Trojan Horse" pathogen-targeting technology, which combats antimicrobial resistance (AMR) with reduced toxicity and enhanced efficacy.
Its lead drug, NV-387, has shown promising antiviral results, positioning NanoViricides (NYSE-A:NNVC) as a leader in tackling AMR and major viral infections.